Chemours Targets $800M–$900M Adjusted EBITDA for 2026, Focusing on Cash Flow and Deleveraging

Chemours has set an adjusted EBITDA target of $800 million to $900 million for 2026, with a strategic focus on cash flow generation and deleveraging.

20 Feb, 17:16 — 20 Feb, 17:16